Literature DB >> 12384813

Investigation of bone disease using isomerized and racemized fragments of type I collagen.

P A C Cloos1, C Fledelius, S Christgau, C Christiansen, M Engsig, P Delmas, J-J Body, P Garnero.   

Abstract

In the collagen type I C-telopeptide an aspartyl-glycine site within the sequence AHDGGR is susceptible to molecular rearrangement. In newly synthesized collagen this site is in the native form, denoted alpha L. During aging a spontaneous reaction occurs resulting in three age-modified forms: an isomerized form (beta L) a racemized form (alpha D), and an isomerized/racemized form (beta D). In this study, we measured the urinary excretion of the four forms of C-telopeptides (CTX) in healthy adults and in patients with bone diseases. Levels of all CTX forms were higher in healthy postmenopausal women (P<0.001) compared with premenopausal controls. Levels decreased within 3 days of bisphosphonate treatment indicating that all CTX forms reflect bone resorption. In hyperthyroidism, characterized by a generalized increased bone turnover, native (alpha L) and age-modified (beta L, alpha D and beta D) forms increased to a similar extent compared to controls, resulting in normal ratios between the alpha L and age-modified forms of CTX. Conversely, in Paget's disease and prostate cancer-induced bone metastases, conditions characterized by focal increased bone turnover, alpha L CTX levels were more elevated than those of age-related CTX forms, resulting in increased ratios between native and age-modified CTX. For example, the ratio alpha L/alpha D was increased 7-fold in Paget's disease (P<0.001) and 2-fold in prostate cancer-induced bone metastases (P<0.002). In conclusion, the study suggests that in conditions with a localized alteration in bone turnover the ratio between alpha L CTX and the age-modified forms is significantly elevated. This may provide a new diagnostic and monitoring tool for diseases such as metastatic bone cancer and Paget's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384813     DOI: 10.1007/s00223-002-2034-1

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  6 in total

Review 1.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.

Authors:  Shinichi Nagase; Yoshitaka Hashimoto; Maria Small; Michiyo Ohyama; Tomohiro Kuwayama; Steve Deacon
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.

Authors:  Hui Zhao; Kui-Lu Han; Zhi-Yu Wang; Yang Chen; Hong-Tao Li; Jun-Liu Zeng; Zan Shen; Yang Yao
Journal:  Med Sci Monit       Date:  2011-11

4.  Second-harmonic generation imaging of collagen in ancient bone.

Authors:  B Thomas; D McIntosh; T Fildes; L Smith; F Hargrave; M Islam; T Thompson; R Layfield; D Scott; B Shaw; C L Burrell; S Gonzalez; S Taylor
Journal:  Bone Rep       Date:  2017-11-01

Review 5.  Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology.

Authors:  Neel I Nissen; Morten Karsdal; Nicholas Willumsen
Journal:  J Exp Clin Cancer Res       Date:  2019-03-06

6.  Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Authors:  Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen
Journal:  Breast Cancer Res       Date:  2003-05-19       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.